Companies: 49,247 Total Market Cap: 132719472666683.39

Kexing Biopharm

SHA-688136
Healthcare Pharmaceuticals
Rank #8550
Market Cap 1.15 B
Volume 6.61 M
Price 5.78
Change (%) 15.31%
Country or region China China

Kexing Biopharm's latest marketcap:

1.15 B

As of 05/21/2025, Kexing Biopharm's market capitalization has reached $1.15 B. According to our data, Kexing Biopharm is the 8550th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 1.15 B
Revenue (ttm) 194.02 M
Net Income (ttm) 6.19 M
Shares Out 197.76 M
EPS (ttm) 0.03
Forward PE 76.02
Ex-Dividend Date n/a
Earnings Date 08/21/2025
Market Cap Chart
Data Updated: 05/21/2025

Kexing Biopharm's yearly market capitalization.

Kexing Biopharm has seen its market value grow from ¥8.11 B to ¥8.27 B since 2020, representing a total increase of 1.89% and an annual compound growth rate (CAGR) of 0.43%.
Date Market Cap Change (%)
05/21/2025 ¥8.27 B 62.31%
12/31/2024 ¥4.32 B 7.17%
12/29/2023 ¥4.03 B -5.31%
12/30/2022 ¥4.26 B -24.16%
12/31/2021 ¥5.62 B -30.78%
12/31/2020 ¥8.11 B

Company Profile

About Kexing Biopharm Co., Ltd.

Kexing Biopharm Co., Ltd. is a biopharmaceutical company specializing in the research, development, production, and sale of recombinant protein drugs and microbial preparations. Operating in China and internationally, the company focuses on innovative therapies across multiple therapeutic areas.

Key Therapeutic Focus Areas

  • Antiviral
  • Tumor and Immunity
  • Blood Disorders
  • Digestive Diseases
  • Degenerative Diseases

Product Portfolio

Recombinant Protein Drugs:

  • Recombinant human interferon α1b
  • Human erythropoietin
  • Human granulocyte stimulating factor

Other Key Products:

  • Clostridium butyricum combined live bacteria powder
  • Kehuang Capsule (Chinese patent medicine)
  • Entecavir (chemical drug)
  • Liraglutide (human glucagon-like peptide-1)
  • Albumin-Paclitaxel, Infliximab, Bevacizumab
  • Adalimumab, Trastuzumab
  • Neratinib maleate tablets
  • Lenalidomide capsules

Company Background: Founded in 1989 and headquartered in Jinan, China, Kexing Biopharm has established itself as a key player in the biopharmaceutical industry.

Frequently Asked Questions

As of 05/21/2025, Kexing Biopharm (including the parent company, if applicable) has an estimated market capitalization of $1.15 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

Kexing Biopharm global market capitalization ranking is approximately 8550 as of 05/21/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region China
Founded 1989
IPO Date n/a
Employees 947
CEO Yanqing Zhao
Sector Healthcare
Industry Pharmaceuticals
Address No. 2666 Chuangye Road
Jinan, 250200
China
Website https://www.kexing.com
People Also Watch
PSX-GLAXO
1.32 15.31%
PSX-ABOT
3.39 15.31%
SHA-605177
2.49 15.31%
SHA-688189
0.89 15.31%